Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Hexal
BISOHEXAL™ 5 mg film-coated tablets BISOHEXAL™ 10 mg film-coated tablets SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): BISOHEXAL™ 5 mg film-coated tablets BISOHEXAL™ 10 mg film-coated tablets COMPOSITION Each Bisohexal 5 mg film-coated tablet contains 5 mg bisoprolol fumarate (2:1). Bisoprolol is (+)-1-[[alpha-(2-isopropoxyethoxy)-p-tolyl]oxy]-3-(isopropylamino)-2-propanol fumarate (2:1). Each Bisohexal 10 mg film-coated tablet contains 10 mg bisoprolol fumarate (2:1). Bisoprolol is (+)-1-[[alpha-(2-isopropoxyethoxy)-p-tolyl]oxy]-3-(isopropylamino)-2-propanol fumarate (2:1). PHARMACOLOGICAL CLASSIFICATION A.5.2 Adrenolytics (sympathicolytics) PHARMACOLOGICAL ACTION Bisoprolol is a selective beta 1 -adrenoceptor antagonist devoid of intrinsic sympathomimetic and membrane-stabilising activity. Pharmacokinetics: Bisoprolol is well absorbed following oral administration with a resultant bioavailability of about 90%. Bisoprolol undergoes minimal hepatic first-pass metabolism. About 50% of a dose is metabolised in the liver and the remainder is excreted unchanged via the kidneys. The plasma elimination half-life is approximately 10 to 12 hours and the duration of action is about 24 hours. INDICATIONS • Bisohexal is indicated for the management of mild to moderate hypertension and angina pectoris. CONTRA-INDICATIONS • Hypersensitivity to bisoprolol or to any of the ingredients • Uncontrolled asthma • Second and third-degree heart block and bradycardia (less than 50 beats per minute) • Pregnancy and lactation. • Uncontrolled cardiac failure • Metabolic acidosis • Sinus bradycardia (less than 50 beats per minute) • Phaeochromocytoma • Hyperthyroidism, as clinical manifestations may be masked Particular caution should be exercised with patients suffering from the following: asthma, bronchit Read the complete document